How Mounjaro V Wegovy Pricing Works With Our Discount Codes
Mounjaro V Wegovy Discount Codes: Your Complete Savings Guide
When comparing Mounjaro v Wegovy costs, understanding discount codes can significantly impact your treatment budget. EverydayMeds offers two primary codes: FIRST40 for new customers and DOSE25 for returning patients, both applied at checkout to reach our competitive pricing structure. These codes work across our entire Wegovy range, from the £79.99 starter dose through to maintenance therapy.
The key difference in the Mounjaro v Wegovy comparison lies not just in mechanism—Wegovy's semaglutide targets GLP-1 receptors whilst Mounjaro's tirzepatide works on both GIP and GLP-1 pathways—but also in cost accessibility. Our discount system ensures transparent pricing without hidden fees, making Wegovy an economically viable option for long-term weight management alongside a reduced-calorie diet and increased physical activity. Both treatments require prescription-only medicine status and professional clinical assessment.
Wegovy Pricing Structure: From Starter to Maintenance Doses
Understanding Mounjaro v Wegovy costs requires examining the complete dose escalation journey for Wegovy. Our pricing starts at £79.99 for the 0.25mg starter dose (weeks 1-4), progressing to £94.99 for 0.5mg (weeks 5-8), £99.99 for 1mg (weeks 9-12), £139.99 for 1.7mg (weeks 13-16), and finally £209.99 for the 2.4mg maintenance dose. These prices reflect the discount codes applied at checkout, ensuring clarity in your treatment planning.
Bundle options provide convenience for the Mounjaro v Wegovy decision-making process, with our Intro Duo (0.25mg & 0.5mg) available for £169.99, ensuring you have your first two months sorted with Reliable Supply continuity. The Progress Duo at £189.99 covers your 0.5mg and 1mg phases, whilst our Ultimate Stability Trio provides three months of maintenance 2.4mg doses for £649.99. These bundles eliminate multiple ordering whilst maintaining cold-chain integrity throughout your treatment journey.
Clinical Evidence: Mounjaro V Wegovy Treatment Outcomes
The Mounjaro v Wegovy clinical evidence shows both treatments demonstrate significant efficacy in clinical trials. Wegovy's STEP programme, particularly the landmark study by Wilding et al., published in NEJM 2021, demonstrated that patients achieved approximately 15% average weight loss at 68 weeks when combined with lifestyle interventions. The STEP trials consistently showed superior outcomes compared to placebo across multiple populations and settings.
When evaluating Mounjaro v Wegovy evidence, it's important to note that different trial designs, populations, and endpoints make direct comparison challenging. Both treatments require prescription-only medicine status and work through distinct but complementary mechanisms—your prescriber can help determine which approach aligns with your individual clinical profile and treatment goals during the assessment process.
How Wegovy's GLP-1 Mechanism Works in Your Body
Understanding the Mounjaro v Wegovy mechanism difference helps inform treatment choice—Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone. This prescription-only medicine works by reducing appetite signals in your brain's appetite centres, promoting feelings of fullness after smaller meals, and potentially reducing food cravings throughout the day. The once-weekly FlexTouch pen delivers consistent medication levels, supporting sustained appetite control when combined with dietary and exercise modifications. Clinical studies suggest this mechanism may help patients achieve meaningful weight management outcomes over extended treatment periods.
Streamlined Ordering Process: Assessment to Delivery
Getting started with Wegovy through our Mounjaro v Wegovy comparison service involves a straightforward three-step process designed for convenience and clinical safety. Begin with our 3-minute online clinical assessment covering your medical history, current medications, and weight management goals—this ensures appropriate prescribing aligned with MHRA guidance for both treatments. Our qualified prescribers review your assessment within 3 working days (or 24 hours with express service), determining suitability and providing personalised treatment recommendations. Once approved, your medication ships via next-day delivery using temperature-controlled cold-chain logistics, ensuring Wegovy arrives in optimal condition ready for immediate use. The entire process maintains clinical governance standards whilst prioritising patient convenience and treatment accessibility.
Storage and Practical Considerations: Wegovy Advantage
The Mounjaro v Wegovy storage comparison reveals important practical differences for treatment planning and lifestyle integration. Wegovy offers superior travel flexibility, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day limit—this advantage proves invaluable for business travel, holidays, or variable schedules. Store unused pens in your fridge at 2-8°C until first use, then follow the dose escalation schedule starting with 0.25mg weekly injections for the first month. The FlexTouch pen system provides user-friendly administration with clear dose windows and comfortable injection experience. Regular dose escalation prevents tolerance development whilst minimising potential gastrointestinal adjustment during your treatment progression through to 2.4mg maintenance therapy.
Discount Code Strategy: Maximising Your Mounjaro V Wegovy Investment
Smart planning around Mounjaro v Wegovy discount codes can optimise your treatment investment over the complete dose escalation timeline. New customers benefit from our FIRST40 code applied at checkout, reaching the competitive prices listed throughout our range, whilst returning customers use DOSE25 for continued savings on subsequent orders. Bundle purchases provide additional value through convenience—fewer individual orders, Reliable Supply continuity, and single delivery charges—particularly valuable during dose transition phases.
The Mounjaro v Wegovy cost comparison extends beyond initial pricing to include long-term treatment sustainability, prescription renewal processes, and ongoing clinical support included in our service. Our GPhC-registered status (#9012878) ensures medication authenticity and proper storage throughout the supply chain, protecting your investment in genuine pharmaceutical-grade treatment. Consider your complete treatment timeline when comparing options, as both Wegovy and Mounjaro require sustained use for optimal outcomes according to clinical trial data.
Make Your Choice: Both Treatments Available at EverydayMeds
Your Mounjaro v Wegovy decision ultimately depends on individual clinical factors, lifestyle preferences, and budget considerations—both treatments are available through EverydayMeds with identical clinical assessment standards and delivery services. Use discount code FIRST40 for new customer savings or DOSE25 for returning patients, applied automatically at checkout to access our competitive Wegovy pricing structure starting from £79.99. Our qualified prescribers provide personalised guidance during the clinical assessment, helping determine which treatment approach aligns with your specific medical profile and weight management objectives. Visit our Wegovy collection at https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and take the first step towards professional weight management support with transparent pricing and genuine pharmaceutical care.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
